<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" 
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://openbell.ai/</loc>
    <lastmod>2026-11-18T01:37:20.491Z</lastmod>
    <changefreq>hourly</changefreq>
    <priority>1.0</priority>
  </url>
  <url>
    <loc>https://openbell.ai/support</loc>
    <lastmod>2026-11-18T01:37:20.491Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.7</priority>
  </url>
  <url>
    <loc>https://openbell.ai/privacy</loc>
    <lastmod>2026-11-18T01:37:20.491Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://openbell.ai/terms</loc>
    <lastmod>2026-11-18T01:37:20.491Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://openbell.ai/feed.json</loc>
    <lastmod>2026-11-18T01:37:20.491Z</lastmod>
    <changefreq>hourly</changefreq>
    <priority>0.8</priority>
  </url>
  <url>
    <loc>https://openbell.ai/news/COST:1794962504142</loc>
    <lastmod>2026-11-18T00:41:44.142Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/COST/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Social Media Discussion: $COST</image:title>
      <image:caption>Bullish. Costco’s value-focused customer service and iconic $1.50 hot dog are praised over Big Tech’s perceived greed; a separate post touts Costco’s potential rise from $50 to $500.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/MSFT:1794962501825</loc>
    <lastmod>2026-11-18T00:41:41.825Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/MSFT/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Social Media Discussion: $MSFT</image:title>
      <image:caption>Sentiment: Bearish. Key themes: Redditors warn Anthropic’s IPO may be priced to favor insiders and institutions over retail investors; Microsoft’s board opposes shareholder proposals for human-rights due diligence and environmental review.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/NVDA:1794962496980</loc>
    <lastmod>2026-11-18T00:41:36.980Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/NVDA/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Social Media Discussion: $NVDA</image:title>
      <image:caption>Sentiment: Mixed. Theme: Nvidia’s record Q3 revenue and AI-chip demand drew bullish attention, while CEO-return rumors and new export-control oversight fueled uncertainty.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/NVDA:1794960091000</loc>
    <lastmod>2026-11-18T00:01:31.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/NVDA/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>NVIDIA Reports Financial Results for Third Quarter Fiscal 2027</image:title>
      <image:caption>NVIDIA reported third-quarter fiscal 2027 revenue of $115.8 billion, up 103% year over year and 20% sequentially. Data Center revenue rose 110% year over year to $107.6 billion, while GAAP and non-GAAP diluted earnings per share were $2.70 and $2.68, respectively. The company said $227.3 billion remained under its share repurchase authorization, following a $150 billion increase approved in September 2026. NVIDIA also declared a quarterly dividend of $0.25 per share, payable December 23, 2026.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/DLB:1794956541000</loc>
    <lastmod>2026-11-17T23:02:21.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/DLB/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Dolby Laboratories Reports Fiscal Q4 2026 Financial Results and Provides Q1 2027 Outlook</image:title>
      <image:caption>Dolby Laboratories reported fiscal Q4 2026 revenue of $373.5 million, slightly above the $372.8 million FactSet consensus, and adjusted EPS of $1.25 versus the $1.20 estimate. For fiscal Q1 2027, the company forecast revenue of $285 million to $305 million, well below the $359.3 million consensus, and adjusted EPS of $0.41 to $0.56, compared with the $1.12 estimate.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/IONS:1794956519000</loc>
    <lastmod>2026-11-17T23:01:59.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/IONS/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Ionis Pharmaceuticals Announces Positive Two-Year Data for Diranersen in Alzheimer&#39;s Disease</image:title>
      <image:caption>Ionis Pharmaceuticals said its partner Biogen presented positive Week 96 results from the Phase 2 CELIA study of investigational tau-targeting therapy diranersen at the CTAD 2026 conference. The data showed continued clinical benefit and slower decline across measured endpoints in patients with early Alzheimer’s disease. The announcement highlights progress in Ionis’s neurology pipeline; the article reported no financial figures or stock-price impact.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/AMRX:1794956510000</loc>
    <lastmod>2026-11-17T23:01:50.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/AMRX/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Amneal Pharmaceuticals Receives European Commission Marketing Authorization for Adcomfo® (omalizumab)</image:title>
      <image:caption>The European Commission granted marketing authorization for Amneal Pharmaceuticals’ Adcomfo® (omalizumab), a biosimilar to XOLAIR®, for eligible patients with severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria. Developed by Kashiv BioSciences with Alvotech, the approval follows a positive EMA committee opinion in September 2026 and UK authorization in March 2026. Amneal is continuing to seek U.S. regulatory approval; the article reports no financial results or stock-price impact.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/BIIB:1794956483000</loc>
    <lastmod>2026-11-17T23:01:23.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/BIIB/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Biogen Announces Positive Two-Year Phase 2 Data for Diranersen in Early Alzheimer&#39;s Disease</image:title>
      <image:caption>Biogen reported positive two-year Phase 2 CELIA study results for investigational tau-targeting therapy diranersen in early Alzheimer’s disease. At Week 96, the 60 mg twice-yearly regimen slowed decline on the CDR-SB scale by 38% versus placebo, a 1.09-point treatment difference, with reported benefits across cognition, function and disease progression. Biogen is evaluating diranersen as a potential approach targeting core Alzheimer’s pathologies.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/GLAD:1794954790000</loc>
    <lastmod>2026-11-17T22:33:10.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/GLAD/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Gladstone Capital Corporation Reports Fiscal Fourth Quarter 2026 Results</image:title>
      <image:caption>Gladstone Capital Corporation reported fiscal fourth-quarter 2026 results for the period ended September 30, 2026, including a decline in net investment income. The business development company provides debt and equity capital to lower middle-market U.S. businesses; the article gives no specific financial figures or stock-price movement.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/LUCK:1794954787000</loc>
    <lastmod>2026-11-17T22:33:07.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/LUCK/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Lucky Strike Entertainment Receives Take-Private Proposal from CEO</image:title>
      <image:caption>Lucky Strike Entertainment CEO and Chairman Thomas Shannon proposed taking the company private for $4.35 per share. The company’s stock price rose notably after the proposal was announced; no financial results or further deal terms were reported.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/AUNA:1794954725000</loc>
    <lastmod>2026-11-17T22:32:05.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/AUNA/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Auna Announces 3Q26 Financial Results</image:title>
      <image:caption>Auna S.A., a healthcare platform operating in Mexico, Peru, and Colombia, announced unaudited financial results for the third quarter of 2026, covering the period ended September 30. The article provides no revenue, profit, growth, or stock-price figures.</image:caption>
    </image:image>
  </url>
</urlset>